Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 | Dec-31-16 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 8-K | 10-K | 10-K |
| Revenues: |
| Trauma and deformity | 85.1 | 65.8 | 47.7 | 49.4 | 39.7 | | 32.8 | |
| Scoliosis | 33.4 | 28.0 | 20.7 | 21.5 | 16.7 | | 11.6 | |
| Sports medicine/other | 3.8 | 4.2 | 2.7 | 1.7 | 1.2 | | 1.2 | |
| Total revenues | 122.3 | 98.0 | 71.1 | 72.6 | 57.6 | 57.6 | 45.6 | 37.3 |
| Revenue growth [+] | 24.7% | 37.9% | -2.0% | 26.0% | 26.2% | | 22.3% | 20.3% |
| Trauma and deformity | 29.2% | 38.1% | -3.4% | 24.4% | 21.0% | | | |
| Scoliosis | 19.2% | 35.2% | -3.5% | 28.9% | 43.8% | | | |
| Sports medicine/other | -8.8% | 56.7% | 57.0% | 41.1% | -2.6% | | | |
| Cost of goods sold | 31.6 | 24.6 | 16.0 | 17.9 | 14.9 | 14.9 | 11.2 | 10.9 |
| Gross profit | 90.7 | 73.4 | 55.0 | 54.6 | 42.7 | 42.7 | 34.5 | 26.4 |
| Gross margin | 74.1% | 74.9% | 77.4% | 75.3% | 74.2% | 74.2% | 75.5% | 70.7% |
| Selling, general and administrative [+] | 104.4 | 85.7 | 70.2 | 57.9 | 47.5 | 47.5 | 37.5 | 28.3 |
| Sales and marketing | 45.1 | 39.7 | 31.9 | 31.3 | 26.6 | 26.6 | 20.5 | 16.7 |
| General and administrative | 59.4 | 46.1 | 38.3 | 26.7 | 20.9 | 20.9 | 17.0 | 11.6 |
| Research and development | 8.0 | 5.5 | 5.3 | 5.7 | 4.7 | 4.7 | 3.4 | 2.2 |
| Other operating expenses | | 0.2 | 6.3 | | | | | 2.0 |
| EBITDA [+] | -8.7 | -7.3 | -18.7 | -4.4 | -6.7 | -6.7 | -4.1 | -4.2 |
| EBITDA growth | 18.3% | -60.8% | 325.4% | -33.9% | 63.8% | | -3.7% | -10.8% |
| EBITDA margin | -7.1% | -7.5% | -26.4% | -6.1% | -11.6% | -11.6% | -8.9% | -11.3% |
| Depreciation | 7.1 | 6.1 | 4.8 | 3.8 | 2.5 | 2.9 | 2.2 | 1.9 |
| EBITA | -15.8 | -13.5 | -23.5 | -8.2 | -9.2 | -9.6 | -6.2 | -6.1 |
| EBITA margin | -12.9% | -13.8% | -33.1% | -11.3% | -15.9% | -16.6% | -13.6% | -16.3% |
| Amortization of intangibles | 6.0 | 4.5 | 3.2 | 0.9 | 0.4 | | 0.2 | 0.0 |
| EBIT [+] | -21.8 | -18.0 | -26.8 | -9.1 | -9.6 | -9.6 | -6.5 | -6.1 |
| EBIT growth | 20.9% | -32.6% | 194.8% | -5.0% | 47.6% | | 5.6% | -7.1% |
| EBIT margin | -17.8% | -18.4% | -37.6% | -12.5% | -16.6% | -16.6% | -14.2% | -16.4% |
| Non-recurring items [+] | 3.6 | | | | | | | |
| Asset impairment | 3.6 | | | | | | | |
| Interest expense | 2.4 | 2.2 | 3.4 | 3.5 | 2.3 | 2.3 | 2.5 | 1.5 |
| Interest expense | 2.4 | 2.2 | 3.4 | 3.5 | 2.3 | 2.3 | 2.5 | 1.5 |
| Other income (expense), net [+] | 24.1 | 2.9 | -3.5 | -0.1 | -0.2 | -0.2 | 0.0 | 1.0 |
| Litigation settlement | | 0.2 | 6.3 | | | | | |
| Change in value of contingent liability | -25.9 | -1.8 | 3.5 | | | | | |
| Other | -1.8 | 1.1 | 0.0 | -0.1 | -0.2 | 0.2 | 0.0 | 1.0 |
| Pre-tax income | -3.7 | -17.4 | -33.7 | -12.7 | -12.0 | -12.0 | -9.0 | -6.6 |
| Income taxes | -4.9 | -1.1 | -0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 134.1% | 6.5% | 2.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 1.3 | -16.3 | -32.9 | -12.7 | -12.0 | -12.0 | -23.5 | -12.4 |
| Net margin | 1.0% | -16.6% | -46.3% | -17.5% | -20.9% | -20.9% | -51.6% | -33.4% |
| |
| Basic EPS [+] | $0.06 | ($0.84) | ($1.82) | ($0.87) | ($0.96) | ($0.96) | ($5.86) | ($7.14) |
| Growth | -107.2% | -53.7% | 110.3% | -9.3% | -83.7% | | -17.9% | -1.9% |
| Diluted EPS [+] | $0.06 | ($0.84) | ($1.82) | ($0.87) | ($0.96) | ($0.96) | ($5.86) | ($7.14) |
| Growth | -107.1% | -53.7% | 110.3% | -9.3% | -83.7% | | -17.9% | -1.9% |
| |
| Dividends per share [+] | | | | | | | $1.48 | |
| Growth | | | | | -100.0% | | | |
| |
| Shares outstanding (basic) [+] | 20.7 | 19.3 | 18.1 | 14.6 | 12.6 | 12.6 | 4.0 | 1.7 |
| Growth | 7.5% | 6.7% | 23.5% | 16.4% | 212.8% | | 130.3% | 0.0% |
| Shares outstanding (diluted) [+] | 20.9 | 19.3 | 18.1 | 14.6 | 12.6 | 12.6 | 4.0 | 1.7 |
| Growth | 8.7% | 6.7% | 23.5% | 16.4% | 212.8% | | 130.3% | 0.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|